Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19865656 | 0.84 | PDPK1 (0.46) | TAS1R3TAS1R1TAS1R2HTR2AHTR2C | |
| SCHEMBL16252290 | 0.79 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2SCN3A | |
| SCHEMBL18435285 | 0.79 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2SCN3A | |
| SCHEMBL19865632 | 0.78 | LRRK2 (0.47) | LMNA | |
| SCHEMBL25516793 | 0.78 | SRD5A1 (0.43) | TAS1R3TAS1R1TAS1R2HTR2AHTR2C | |
| SCHEMBL10159937 | 0.77 | PDPK1 (0.53) | TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL13164295 | 0.77 | PDPK1 (0.53) | TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL12130659 | 0.77 | PDPK1 (0.53) | TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL15577013 | 0.75 | HTR2C (0.58) | TAS1R3TAS1R1TAS1R2HTR2AHTR2C | |
| SCHEMBL18468830 | 0.75 | HTR2C (0.58) | TAS1R3TAS1R1TAS1R2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | TAS1R3 4061/4885TAS1R1 3875/4885TAS1R2 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.